Flualprazolam Stats & Data

Flualprazolam was first synthesized in 1976 as part of broader benzodiazepine research, representing the triazolo analog of fludiazepam and structurally related to alprazolam as its 2'-fluoro derivative. Despite its early synthesis, the compound was never developed for pharmaceutical use and remained largely unknown for over four decades. The substance emerged on the online research chemical market in 2017, joining a growing number of novel benzodiazepine analogs being sold as designer drugs. Swedish forensic authorities first definitively identified flualprazolam in circulation in 2018. According to some reports, the compound has been marketed or deceptively sold as a replacement for alprazolam, the widely prescribed pharmaceutical benzodiazepine, despite the two substances differing in substantive ways. Its appearance on the designer drug market subsequently prompted international regulatory attention, with the World Health Organization recommending it for scheduling in December 2019.

Flualprazolam likely has a low toxicity relative to dose. However, it is potentially lethal when mixed with depressants like alcohol or opioids. It is strongly recommended that one use harm reduction practices when using this substance.

Effects aggregated from 4 experience reports (4 single-substance Erowid)

Each bar is the share of reports mentioning the effect; its whisker, and the band on the rows below, is the 95% interval: where the share could plausibly be with other reports of the same kind.

Too few reports for bars: these effects come from 4 single-substance Erowid reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

From 5 of 14 recorded dose entries: those that state a weight (mg, g or µg), in routes with at least five of them. Values above Q3 + 3×IQR, far above what people typically take, are left out; they can include real heavy doses and overdoses, not only mistakes.